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ABSTRACT: Efficient bacterial cell factories are important for the
screening and characterization of potent antimicrobial peptides
such as lantibiotics. Although lantibiotic production systems have
been established in Lactococcus lactis and Escherichia coli, the
industrial workhorse Bacillus subtilis has been left relatively
unexplored as a lantibiotic production host. Therefore, we tested
different B. subtilis strains for their ability to produce lantibiotic
peptides by using the subtilin modification and transport enzymes
derived from the natural subtilin producer B. subtilis ATCC 6633.
Our study shows that although B. subtilis ATCC 6633 and 168 are
able to produce various processed lantibiotic peptides, an evident
advantage of using either the 8-fold protease-deficient strain WB800 or the genome-minimized B. subtilis 168 strain PG10 is the lack
of extracellular serine protease activity. Consequently, leader processing of lantibiotic precursor peptides is circumvented and thus
potential toxicity toward the production host is prevented. Furthermore, PG10 provides a clean secondary metabolic background
and therefore appears to be the most promising B. subtilis lantibiotic production host. We demonstrate the production of various
lantibiotic precursor peptides by PG10 and show different options for their in vitro activation. Our study thus provides a convenient
B. subtilis-based lantibiotic production system, which facilitates the search for novel antimicrobial peptides.
KEYWORDS: miniBacillus, lantibiotics, microbial cell factory, expression systems, extracellular serine proteases
Due to the global problem of antibiotic resistant bacteriathere is an increasing interest in novel bioactive natural
compounds. A promising source is constituted by ribosomally
synthesized and post-translationally modified peptides (RiPPs)
which display a broad variety of bioactivities.1 Within the
RiPPs, the class of lantibiotics is of great interest because of
their therapeutic potential and the possibility to use them as a
food preservative. Lantibiotic peptides are naturally produced
mainly by Gram-positive bacteria and harbor dehydrated
residues and (methyl)lanthionine rings, of which the latter is
important for their antimicrobial activity to a broad range of
particularly Gram-positive bacteria.2,3
In the case of class I lantibiotics, the lantibiotic gene cluster
generally consists of a structural gene (lanA), genes encoding
the modification enzymes (lanB and lanC), an ATP binding
cassette (ABC) transporter (lanT), a leader protease (lanP),
regulatory elements (lanRK) and proteins providing immunity
to the producer organism (lanFEG and lanI).4,5 After
ribosomal synthesis, the lantibiotic precursor peptide is
composed of a leader and a core peptide of which the N-
terminal leader peptide is important for guiding the precursor
peptide to the modification, transport, and leader protease
enzymes and for keeping the core peptide inactive during
maturation. After leader peptide cleavage, generally by a
specific protease, the mature antimicrobially active core
peptide is released.
Although genome mining approaches greatly facilitate the
identification of lantibiotic peptides, further characterization
can be hampered due to difficulties in finding the right
conditions for expression of the lantibiotic peptide by the
natural microbial producer. Since chemical synthesis of
lantibiotics has proven to be quite challenging, heterologous
production and modification by a suitable microbial host in
most cases enables researchers to obtain sufficient amounts for
further investigation of potent lantibiotic peptides and their
derivatives.6 Thanks to the heterologous expression systems
that were established in Lactococcus lactis and Escherichia coli,
various novel lantibiotic peptides have been discovered and
characterized.7−10 Nevertheless, some evident obstacles have
been encountered when using these production platforms. For
instance, a disadvantage of using L. lactis as a heterologous
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production host is the limited final cell density due to medium
acidification by lactic acid that is produced during the
fermentation process.11 Although pH-controlled fermentations
lead to higher cell densities, this may result in a reduced
activity and stability of the lantibiotic peptide.12 By employing
E. coli as lantibiotic production host, higher cell densities and
thus potentially higher production yields can be reached.
However, heterologous expression in E. coli often requires
additional downstream processing steps due to intracellular
accumulation of the expressed peptide and the herewith
associated higher chance of the formation of inclusion bodies.
Another promising lantibiotic production host that possibly
could overcome the previously mentioned limitations is the
industrial workhorse Bacillus subtilis. B. subtilis is already
extensively used for the commercial production of various
proteins, but has been left relatively unexplored as potential
microbial chassis for lantibiotics. In addition to having a GRAS
(generally recognized as safe) status like L. lactis, and being
able to grow to higher cell densities without medium
acidification similar to E. coli, a great advantage of using B.
subtilis as production host is its high natural secretion
capacity.13,14 Moreover, natural competence and efficient
homologous recombination are features of B. subtilis that
enable genetic manipulation in a relatively easy and stable
manner. Furthermore, the availability of a vast extent of
synthetic biology tools and optimized strains make B. subtilis
an attractive heterologous production host.14,15
Several attempts have been made to employ the natural
producer of subtilin B. subtilis ATCC 6633 or the laboratory
strain B. subtilis 168 as a production host for lantibiotics.16−18
For instance, nisin could be produced by B. subtilis ATCC
6633 after optimizing the leader peptide that was fused to the
nisin core peptide.17 In addition, a B. subtilis 168 strain
producing antimicrobially active subtilin was constructed by
integration of a 40 kb DNA region, including the subtilin gene
cluster, of B. subtilis ATCC 6633.18 Furthermore, Hansen et al.
could diminish the sensitivity of B. subtilis 168 to nisin by
overexpression of genes involved in the natural defense
mechanism toward nisin and by introduction of the nisin
immunity genes (nisFEG and nisI).19 Although a 15-fold
increase in nisin resistance could be obtained, Hanssen et al.
acknowledge that the nisin level that was maximally tolerated
(600 mg/L) is insufficient to enable commercial production of
nisin by this engineered B. subtilis strain.
The degree of success of the past attempts to use B. subtilis
as a lantibiotic production host likely has been limited by two
major hurdles: (1) proteolytic processing of the lantibiotic
precursor peptide by native extracellular serine protease
activity of the B. subtilis strains that were employed, which
likely caused product toxicity of the released and activated
product to the host strain, and (2) the lack of a lantibiotic
Figure 1. Overview of lantibiotic production platforms in different B. subtilis host strains. The genetics of the different lantibiotic expression systems
and relevant characteristics of each B. subtilis host strain are shown. Extracellular proteases and native bioactive peptides (e.g., sublancin, surfactin,
and subtilosin) of B. subtilis are visualized as red split circles and blue structures, respectively. (a) Lantibiotic production system in B. subtilis ATCC
6633 in which the spaS gene in the subtilin gene cluster is replaced by a gene encoding a hybrid peptide composed of the subtilin leader (spaSL;
containing the NisP cleavage site “ASPR”) followed by a core peptide of interest (lanAC). The expression systems in B. subtilis 168 (b) and WB800
(c) contain spaBTC controlled by the xylose-inducible promoter (PxylA), and the lantibiotic structural gene encoding a hybrid peptide composed of
the subtilin leader peptide and a core peptide of interest regulated by the IPTG-inducible hyper-spank promoter (Pspank‑hy) integrated in the thrC
and amyE locus, respectively. (d) Although three different expression systems were tested in miniBacillus PG10, the expression system in which
both the structural gene and spaBTC are integrated in the amyE locus and controlled by IPTG-inducible promoters (Pspank‑hy and Pspank) was applied
for expression of various core peptides. In the case of production platforms a and b, lantibiotic precursor peptides are processed into their mature
antimicrobially active form by existing extracellular serine protease activity. Production systems c and d enable the production of lantibiotic
precursor peptides, due to the absence of the five extracellular serine proteases as a result of either the direct deletion of eight extracellular proteases
or genome-reduction by 36%. PG10 (d) provides a clean secondary metabolic background due to deletion of genes involved in production of native
antimicrobial compounds.
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expression system that is inducible and composed of a minimal
set of heterologous genes. While the benefits of B. subtilis as a
bacterial cell factory are well-known, the previous studies did
not investigate the potential of B. subtilis as a lantibiotic
production host thoroughly. Therefore, we reasoned that it
would be worthy to explore a lantibiotic production platform
in B. subtilis in more detail. Moreover, with the development of
several improved B. subtilis expression hosts in recent years,
such as the 8-fold protease-deficient WB800 strain20 and the
genome-minimized B. subtilis 168 strain PG10,21 limitations of
the parental B. subtilis strains might be overcome.22 Thus, in
this study, we compared various B. subtilis strains as production
hosts for lantibiotic peptides and investigated different
inducible expression systems. By employing the subtilin
modification and transport machinery (SpaBTC), we show
that PG10 is a convenient microbial chassis for the production
of various lantibiotic precursor peptides that can be activated in
vitro at a later stage.
Our study provides a versatile platform for the screening and
characterization of potent lanthipeptides that can be used in
addition to previously constructed systems in L. lactis and E.
coli.
■ RESULTS AND DISCUSSION
Production of Processed and Antimicrobially Active
Lantibiotic Peptides by B. subtilis ATCC 6633 and B.
subtilis 168. Although with restricted success, previous work
demonstrated the production of either nisin or subtilin by B.
subtilis ATCC 6633 or B. subtilis 168, respectively. However,
these studies were quite limited and focused only on the
production of one lantibiotic peptide. With respect to a more
thorough exploration of general lantibiotic production plat-
forms in B. subtilis, we re-evaluated B. subtilis ATCC 6633 and
B. subtilis 168 as production hosts. B. subtilis 168 was chosen
because it is the best-characterized and most frequently applied
B. subtilis strain. In contrast, B. subtilis ATCC 6633 is not
commonly used as expression host, but might provide the most
optimal expression level of the different genes in the lantibiotic
gene cluster, since it is the natural producer of subtilin.
Furthermore, genetic engineering of B. subtilis ATCC 6633 is
still feasible by artificial expression of the competence
transcription factor ComK.23
To assess B. subtilis ATCC 6633 as a lantibiotic production
host, we replaced the spaS gene in the subtilin gene cluster by a
gene encoding a hybrid peptide composed of the subtilin
leader peptide and the core peptide of either nisin (NisA) or
flavucin (FlaA) (Figure 1A). Whereas nisin and its biosynthesis
machinery have been thoroughly studied,2 flavucin has recently
been discovered by genome-mining and heterologous
production in L. lactis by employing the nisin modification
and transport machinery.7 For the production of lantibiotic
peptides by B. subtilis 168 (Figure 1B), we introduced the
transcriptional unit encoding spaBTC in the thrC locus and
controlled the expression by a xylose-inducible promoter. In
addition, the structural lantibiotic gene was inserted in the
amyE locus and regulated by the slightly stronger and IPTG-
inducible hyperspank promoter. By using these two inducible
promoters, we attempted to resemble the relative higher
expression level of spaS compared to spaBTC in B. subtilis
ATCC 6633,24 while also circumventing the need for
introduction of the spaRK genes in B. subtilis 168. As structural
genes we chose the same hybrid peptides as used for B. subtilis
ATCC 6633 as well as the native spaS gene, since this might
provide the most optimal combination with spaBTC. With
respect to the subtilin-nisin and subtilin-flavucin hybrid
peptides in B. subtilis ATCC 6633 and B. subtilis 168, we
changed the four C-terminal residues (ITPQ) of the subtilin
leader peptide into the NisP cleavage site of the nisin leader
peptide (ASPR) to reduce the chance of leader peptide
removal by general B. subtilis proteases. Also, this might allow
in vitro leader cleavage by either NisP or trypsin at a later stage.
To test the lantibiotic expression systems in B. subtilis
ATCC 6633 and B. subtilis 168, mid-to-late exponentially
growing cultures were induced with either supernatant (0.2%)
of ATCC 6633 wild type strain (containing subtilin) or with
xylose and IPTG, respectively. The presence of subtilin in the
growth medium of B. subtilis ATCC 6633 should induce the
expression of spaS, spaIFEG, and the structural gene via the
two-component system SpaRK. After TCA-precipitation of the
culture supernatant, antimicrobial activity was observed for B.
subtilis ATCC 6633 and B. subtilis 168 expressing the flavucin
core peptide as well as for the B. subtilis 168 strain with the
native spaS gene, but not for the strains containing the nisin
core peptide (Figure 2A,B). Possibly, modification of nisin by
SpaB and SpaC is less efficient compared to the subtilin and
flavucin core peptides resulting in the presence of an immature
subtilin-nisin precursor peptide that is more prone to
degradation. This agrees with the fact that Rintala et al.
could only produce nisin in B. subtilis ATCC 6633 after using a
subtilin-nisin hybrid leader mainly composed of the nisin
leader, which likely improved the modification efficiency of the
nisin core peptide.17 Strikingly, we observed that the
antimicrobial activity in the culture supernatant of ATCC
6633 spaS::spaASPRL-f laA was independent of induction with
subtilin, indicating that leaky expression from the subtilin gene
cluster was already sufficient for the production of anti-
microbially active flavucin (possibly due to some autoinduction
by flavucin). Furthermore, leader processing already occurred
fully or to a large extent by B. subtilis protease activity for both
lantibiotic expression systems in B. subtilis ATCC 6633 and B.
subtilis 168. In the case of B. subtilis 168 containing spaS
Figure 2. Antimicrobial assays to assess the production of lantibiotic
peptides byB. subtilis ATCC 6633 and B. subtilis 168. TCA-
precipitated supernatant was analyzed of (a) B. subtilis ATCC 6633
or (b) B. subtilis 168 strains containing spaBTC and various lantibiotic
structural genes: subtilin-nisin hybrid peptide with ASPR as cleavage
site (nis), subtilin-flavucin hybrid peptide with ASPR as cleavage site
(fla), or native subtilin (spa): (+) with induction of the lantibiotic
genes; (−) without induction. The black dots indicate where TCA-
precipitated supernatant samples were pipetted either alone (upper
half of the plate) or in combination with a protease sample (lower half
of the plate); trypsin in the case of ASPR-containing peptides, B.
subtilis 168 supernatant in the case of native subtilin. In image a, “△+”
represents the TCA-precipitated supernatant of B. subtilis ATCC 6633
ΔspaS which was used as a negative control, and “+” indicates a
positive control sample for activation by trypsin.
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processing seemed to have occurred fully, since in vitro
incubation with supernatant of B. subtilis 168 did not increase
the size of the growth inhibition zone. Protease activity of both
B. subtilis ATCC 6633 and B. subtilis 168 processed the
subtilin-flavucin hybrid peptide to a large extent but not
completely, since the growth inhibition zone slightly increased
upon addition of trypsin. In agreement with this, MALDI-TOF
MS indicated the presence of flavucin without the leader as
well as with one to four of the C-terminal residues (ASPR) of
the leader in the TCA-concentrated supernatant of B. subtilis
ATCC 6633 spaS::spaASPRL-f laA (Supplementary Figure 1).
Prevention of Leader Processing by Using B. subtilis
WB800 or miniBacillus PG10 as Lantibiotic Production
Host. Although functional lantibiotic production platforms
could be established in B. subtilis ATCC 6633 and B. subtilis
168, a clear disadvantage of these host strains is the occurrence
of leader processing by existing and ubiquitous extracellular
serine protease activity. Leader processing causes the modified
lantibiotic core peptide to become antimicrobially active.
Concomitantly, this hampers the application of B. subtilis
ATCC 6633 and B. subtilis 168 as lantibiotic production hosts
due to potential product toxicity when expressing mutant or
novel lantibiotics. To circumvent the need for specific
immunity genes and to achieve the production of inactive
lantibiotic precursor peptides of various nature, we introduced
a lantibiotic expression system in the 8-fold protease-deficient
strain WB80020 and the B. subtilis 168 derived miniBacillus
PG10 of which the genome has been reduced by 36%.21 Both
WB800 and PG10 lack all the five extracellular serine proteases
of which at least AprE, WprA, and Vpr have been suggested to
be involved in leader processing of presubtilin.25 Moreover,
PG10 does not secrete other antimicrobial compounds (e.g.,
sublancin, surfactin, and subtilosin) and thereby provides a
cleaner secondary metabolic background.
First, we assessed whether WB800 and PG10 could be used
for the production of the precursor peptide of subtilin,
presubtilin (Figure 1C,D). For WB800, the same integration
vectors were applied as used previously for 168 with the
expression of spaBTC regulated by the xylose-inducible
promoter. Since the xylose operon including the xylose
repressor (XylR) had been deleted in PG10, and because
PG10 is a cleaner host compared to WB800, we chose to test
three different expression systems in PG10. For the first
system, we reintroduced xylR under control of its own
promoter in the sacA locus to reestablish the inducible
expression of spaBTC from PxylA (thrC locus) and to combine
this with the expression of spaS from the hyperspank promoter
(amyE locus), similar to the expression systems in B. subtilis
168 and WB800. As a second option, the expression of spaBTC
was controlled by the Pspank promoter and this operon was
inserted downstream of the spaS gene in the amyE locus
(Figure 1D). The Pspank promoter is also inducible with IPTG,
but is about six times less strong compared to Pspank‑hy which
should again allow for a relative higher expression level of spaS
compared to spaBTC. Furthermore, we tested whether the
subtilin-regulated expression (SURE) system26 could be used
for the production of presubtilin. In this case, the two-
component regulatory system spaRK with its natural promoter
was inserted in the thrC locus, while the amyE locus contained
spaBTC and spaS controlled by their natural promoters. The
addition of subtilin to the growth medium should lead to
activation of SpaRK followed by induction of gene expression
of spaBTC and spaS.
As visible in Figure 3A, the TCA-precipitated culture
supernatant of both WB800 and the different PG10 strains
showed antimicrobial activity when mixed with supernatant of
B. subtilis 168, indicating the presence of presubtilin in the
supernatant of these strains. In agreement with this, the
production of presubtilin was confirmed by tricine SDS-PAGE
(Figure 3B) and MALDI-TOF MS (Supplementary Figure 2).
As expected, tricine SDS-PAGE shows substantially less
proteins in the culture supernatant of PG10 compared to
WB800 thereby providing a cleaner production platform for
lantibiotic peptides. This advantage of PG10 was also
supported by the MALDI-TOF MS spectrum of WB800 by
the relatively high abundance of sublancin compared to the
heterologously produced presubtilin. Among the three differ-
ent expression systems in PG10, the IPTG- and subtilin-
controlled expression systems yielded similar amounts of
presubtilin, while the system in which spaBTC expression is
controlled by the xylose-inducible promoter showed the least
production of presubtilin. For the latter system, the production
of presubtilin was likely limited by lack of the AraE transporter
in PG10 which normally facilitates transport of xylose in B.
subtilis.27 Therefore, low intracellular levels of xylose in PG10
probably caused insufficient derepression of spaBTC, thereby
limiting modification and export of presubtilin. Nevertheless,
by using the IPTG- or subtilin-controlled expression system in
Figure 3. Production of presubtilin by B. subtilis WB800 and PG10. Production of presubtilin by WB800 (W) or PG10 (P1−P3) containing
spaBTC and spaS under control of inducible promoters, assessed by (a) antimicrobial activity assay with or without added protease for processing
and (b) tricine SDS-PAGE. TCA-precipitated supernatant was obtained from strains cultured with (+) or without induction (−) of the lantibiotic
genes. P1−P3 represents three different lantibiotic expression systems in PG10: P1, spaS controlled by Pspank‑hy and spaBTC regulated by PxylA by
reintroduction of xylR in PG10; P2, spaS controlled by Pspank‑hy and spaBTC regulated by Pspank; P3, concerns the SURE-regulated expression
system. In image a, black dots indicate where TCA-precipitated supernatant samples were pipetted either alone (upper half of the plate) or in
combination with B. subtilis 168 supernatant for proteolytic activation of presubtilin (lower half of the plate). In image b, the expected mass of
mature presubtilin is 6074 Da.
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PG10, similar production yields could be obtained as with the
lantibiotic production system in WB800. Taken together, these
results show that both WB800 and PG10 are suitable B. subtilis
hosts for the production of lantibiotic precursor peptides from
which the antimicrobially active core peptide later on can be
released in vitro. An additional advantage of PG10 over WB800
is the cleaner secondary metabolic background which simplifies
purification of the lantibiotic precursor peptide of interest.
Production of Various Lantibiotic Precursor Peptides
by PG10. Since the production yield of presubtilin seemed
comparable between WB800 and PG10, we decided to assess
PG10 in more detail as a lantibiotic production host because of
its cleaner secondary metabolic background. Therefore, we
expressed spaBTC in combination with various hybrid
precursor peptides composed of either the native subtilin
leader peptide or ASPR-containing subtilin leader peptide
fused to the core peptide of subtilin, nisin, or flavucin (Table
Table 1. Lantibiotic precursor peptides expressed in miniBacillus PG10a







aspaL indicates the original subtilin leader peptide, whereas spaASPRL is the subtilin leader peptide containing the NisP cleavage site (ASPR).
Leader peptide sequences are displayed in bold.
Figure 4. Production of various lantibiotic precursor peptides by B. subtilis PG10. Production of lantibiotic precursor peptides by PG10 strains
containing Pspank-regulated spaBTC and a particular lantibiotic precursor peptide controlled by Pspank‑hy (integrated in the amyE locus), assessed by
(a) tricine SDS-PAGE and (b) MALDI-TOF MS. The lantibiotic precursor peptide is either composed of the native subtilin leader peptide (spaL)
or the ASPR-containing subtilin leader peptide (spaASPRL) and fused to the core peptide of subtilin (spaS), nisin (nisA), or flavucin (flaA). In
image a, “neg.” represents a negative control sample derived from PG10 containing spaBTC and spaS cultured without induction. In part b, spectra
show the detected mass (in Da) of the highest peak for each of the six different precursor peptides. The theoretical mass of fully dehydrated
precursor peptides without the first methionine is mentioned in parentheses.
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1). Production and secretion of all the various precursor
peptides into the growth medium of PG10 was observed,
including the precursor peptides containing the nisin core
peptide (Figure 4A). Herewith the advantage of a lantibiotic
production system in a B. subtilis strain that lacks extracellular
serine protease activity is clearly demonstrated since even
peptides can be produced that could not be obtained by using
B. subtilis ATCC 6633 or B. subtilis 168 as production host.
Along with a greater variety of peptides, higher production
yields can be obtained with the production of lantibiotic
precursor peptides. Furthermore, MALDI-TOF MS showed
that the detected masses of the various precursor peptides
correlated to the theoretical masses of fully or almost fully
modified precursor peptides (Figure 4B). This indicates that
SpaB and SpaC display a broad substrate specificity, resulting
in a high degree of modification of the various precursor
peptides.
Next, we assessed whether the various precursor peptides
could be processed by protease activity of either a supernatant
of a B. subtilis 168 or a B. subtilis ATCC 6633 ΔspaS overnight
culture, NisP, or trypsin (Table 2 and Supplementary Table 1).
Whereas supernatant of B. subtilis 168 could release
antimicrobially active subtilin from both types of leader
peptides as well as nisin from the native subtilin leader
peptide, it could not activate the precursor peptides containing
flavucin as core peptide. Strikingly, the proteolytic activity in
the supernatant of the B. subtilis ATCC 6633 ΔspaS overnight
culture could only release antimicrobially active subtilin from
the native subtilin leader peptide. These observations agree
with previous speculations28,29 indicating that the substrate
specificity of extracellular serine proteases of B. subtilis is
affected by the N-terminal residues of the core peptide, in
addition to the residues that constitute and precede the
cleavage site. In agreement with this, the first two N-terminal
residues of subtilin are a tryptophan and lysine, while both
nisin and flavucin core peptides start with isoleucine followed
by threonine. Possibly, the N-terminal tryptophan of the
subtilin core peptide plays an important role in presubtilin
processing by B. subtilis extracellular proteases. In addition, our
data suggest that extracellular serine proteases of B. subtilis
ATCC 6633 rely more on the native cleavage site in presubtilin
for release of the subtilin core peptide compared to
extracellular serine proteases of B. subtilis 168. However, the
in vitro conditions used in this experiment might not have been
optimal for the extracellular serine proteases of both B. subtilis
168 and B. subtilis ATCC 6633 in order to process the various
precursor peptides. By varying pH and salt concentration a
broader substrate tolerance might be observed, since these
factors affect the substrate specificity of proteases.29
In addition to the in vitro release of mature subtilin by
proteolytic activity of B. subtilis supernatant, we could release
each of the three core peptides from the ASPR-containing
subtilin leader peptide by using NisP or trypsin. While
antimicrobially active subtilin or nisin could be obtained by
using either NisP or trypsin, flavucin could only be released by
treatment with trypsin. The inability of NisP to release flavucin
might be related to the slight positive charge on the N-terminal
part of the flavucin core peptide compared to the rather neutral
N-terminal part of the subtilin and nisin core peptides. Again,
different reaction conditions might allow the in vitro release of
flavucin from the ASPR-containing subtilin leader peptide by
NisP.
Overexpression of B. subtilis Extracellular Serine
Proteases as in Vitro Leader Processing Tool. The
successful heterologous production of presubtilin and other
precursor peptides in PG10 allowed us to gain more insight in
the proteolytic abilities of the five extracellular serine proteases
(AprE, WprA, Vpr, Bpr, Epr) of B. subtilis. Also, this might
provide a neater way for the in vitro processing of presubtilin
and allow application of these proteases for in vitro processing
of other precursor peptides. Therefore, we overexpressed each
of the proteases, using the coding sequences of B. subtilis
ATCC 6633, in PG10. After induction of protease expression
in PG10, we analyzed whether protease activity in the culture
supernatant could activate the various precursor peptides
produced by PG10. Although WprA was previously detected in
the culture supernatant of B. subtilis 168,29 we also analyzed
the cell lysate of PG10 overexpressing WprA, since it is a cell
wall-associated protease.30 Our results show that the super-
natant of PG10 overexpressing AprE and Bpr as well as the cell
lysate of PG10 WprA could activate presubtilin and presubtilin
containing the NisP cleavage site (Table 2). In contrast, Epr-
and Vpr-containing supernatant could not process any of the
precursor peptides, including the native subtilin precursor
peptide.
Hereby, we provide for the first-time direct evidence for a
prominent role of AprE, WprA, and Bpr in leader peptide
cleavage of presubtilin. Although the proteolytic ability of AprE
and WprA to process presubtilin agrees with the study of
Corvey et al.,25 we did not find a role for Vpr in presubtilin
processing in comparison to the findings of Corvey et al.
Rather, our study reveals Bpr as the third extracellular serine
Table 2. Processing of Various Lantibiotic Precursor Peptides Produced by miniBacillus PG10a
incubated with
Precursor peptide 168* ATCC 6633ΔspaS* NisP Trypsin AprE* WprA# Vpr* Bpr* Epr*
spaL-spaS + + − − + + − + −
spaASPRL-spaS ± − + + ± − − + −
spaL-nisA ± − − − − − − − −
spaASPRL-nisA − − + + − − − − −
spaL-flaA − − − − − − − − −
spaASPRL-flaA − − − ± − − − − −
aThe agar diffusion test was performed with TCA-precipitated supernatant of PG10 strains producing various lantibiotic precursor peptides. TCA-
precipitated supernatant was mixed with culture supernatant (depicted as *) of B. subtilis 168, B. subtilis ATCC 6633 ΔspaS, or PG10 protease
overexpression strains, NisP, trypsin, or cell lysate of PG10 overexpressing WprA (depicted as #). Processing abilities of the different protease
samples were assessed by observation of growth inhibition zones, which were divided in three categories: no growth inhibition zone (diameter <1
mm; indicated by −), growth inhibition zone with a diameter between 1 and 10 mm (indicated by ±), and growth inhibition zone with a diameter
>10 mm (indicated by + ). See Supplementary Table 1 for exact diameters of growth inhibition zones.
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protease capable of activating presubtilin. Although we
provided direct evidence for the proteolytic ability of AprE,
WprA, and Bpr to cleave presubtilin, we cannot rule out a role
for Vpr and Epr in presubtilin processing since factors for
maturation into their active forms might have been lacking in
PG10. With these PG10 strains at hand, future experiments
could provide even more insight in the substrate specificities of
the five extracellular serine proteases of B. subtilis and assess
whether they can be used for the in vitro activation of other
lantibiotic peptides.
■ CONCLUSION
Although various lantibiotic peptides have been successfully
identified via their heterologous production in E. coli or L.
lactis, two beneficial traits of these bacterial hosts can be
combined by employing B. subtilis as an expression host: high
cell density cultures and direct secretion of lantibiotic peptides
into the culture medium. Our study demonstrates that these
benefits indeed can be met and that B. subtilis can serve as an
excellent lantibiotic production host by choosing a B. subtilis
strain that lacks extracellular serine protease activity. In this
way, leader processing during expression of the lantibiotic
genes is prevented, thereby circumventing the major obstacle
of B. subtilis as a production host for lantibiotics. The NisP
cleavage site can be used conveniently in most cases, but if
inefficient also a factor Xa site can be engineered instead, or an
extracellular serine protease of B. subtilis can be attempted. By
employing WB800 or miniBacillus PG10, lantibiotic precursor
peptides can efficiently be produced and secreted. The
production of lantibiotic precursor peptides prevents toxicity
to the production host and alleviates the need of immunity
genes. Furthermore, PG10 provides as additional advantage a
clean secondary metabolic background which might simplify
downstream processing and characterization of the produced
lantibiotic precursor peptide.
Thus, by using the subtilin modification and transport
enzymes the established lantibiotic production platform in
miniBacillus PG10 allows a convenient way to characterize
potent lantibiotic peptides. Furthermore, this opens possibil-
ities for investigation of B. subtilis as an expression host for
other classes of antimicrobial peptides, thereby accelerating the
identification of novel natural products that potentially can be
applied to combat antimicrobial resistance.
■ METHODS
Strains and Plasmids. Bacterial strains and plasmids used
in this study are listed in Supplementary Table 2. B. subtilis
strains were cultured in LB-Lennox medium (Formedium) at
37 °C with aeration. E. coli (MC1061, DH5α or Top10) used
as cloning host and M. luteus used as indicator strain were
grown in LB at 37 °C with aeration. When required, antibiotics
were added to the growth media of B. subtilis at the following
concentrations: 100 μg/mL spectinomycin, 0.5 μg/mL
erythromycin, 12.5 μg/mL lincomycin, or 5 μg/mL
kanamycin. Half of the concentration of antibiotics was used
in the case of liquid cultures of PG10. For E. coli, 100 μg/mL
ampicillin or 100 μg/mL kanamycin was used. Growth media
was supplemented with agar (1.5%) for solid medium.
Construction of Plasmids. Conventional cloning techni-
ques were applied for construction of all plasmids. spa genes
and extracellular serine protease genes were taken from B.
subtil is ATCC 6633 (NCBI Reference Sequence:
NZ_ADGS00000000.1). Oligonucleotides are listed in Supple-
mentary Table 3 and were purchased from Biolegio.
Restriction enzymes, T4 DNA ligase, and Phusion-HF DNA
polymerase were obtained from Thermo Fisher Scientific.
PfuX7 DNA polymerase (purified in our lab) was used for
cloning purposes and colony PCR. Unless otherwise
mentioned, standard restriction−ligation was used for
construction of plasmids. Quick-Fusion ligation was performed
according to manufacturer’s descriptions (Bimake.com). All
constructs were verified by sequencing. B. subtilis 168, WB800,
and pGSP12-containing B. subtilis ATCC 6633 were trans-
formed in Spizizen’s minimal medium as described before,31
except that 2.5 μg/mL erythromycin was added to the culture
medium in the case of ATCC 6633. For transformation of B.
subtilis 168 PG10 carrying the competence genes (comK,
comS) under the control of the mannitol-inducible promoter
(PmtlA),
32 competence was induced by adding 0.5% (w/v)
mannitol.
Lantibiotic Gene Expression Constructs. To construct
pDG1664-PxylA-spaBTC the spaBTC genetic sequence was
obtained from the genomic DNA of B. subtilis ATCC 6633 by
PCR amplification using primer pairs ASRo254 + ASRo255,
followed by NotI and NheI digestion and T4 ligation into
similarly digested pDG1664.
To construct pDR111-Pspank‑hy-spaS, spaS was amplified from
the genomic DNA of B. subtilis ATCC 6633 by using primer
pair ASRo256 + ASRo257. The spaS PCR product was
digested with HindIII and NheI and ligated into HindIII-NheI-
digested pDR111 yielding pDR111-Pspank‑hy-spaS. Overlap
extension PCR was used in order to obtain the pDR111
constructs with different types of lantibiotic core peptides
fused to the native subtilin leader sequence or the subtilin
leader sequence containing the NisP cleavage site (ASPR).
Primer pairs ASRo298 + ASRo241, ASRo290 + ASRo291, and
ASRo294 + ASRo291 were used to amplify the spaS, nisA, and
f laA core peptide sequences from pDR111-Pspank‑hy-spaS,
pNZE3-nisA, and pNZE3-flaA, respectively. To obtain the
ASPR-modified spaS leader sequence for the spaS core peptide
constructs, primer pair ASRo224 + ASRo297 were used.
Primer pairs ASRo224 + ASRo289 and ASRo224 + ASRo288
were used to amplify the native spaS leader sequence or the
spaS leader sequence containing the ASPR cleavage site
respectively for the nisA core peptide constructs. To obtain the
analogous constructs for the f laA core peptide sequence,
primer pairs ASRo224 + ASRo293 and ASRo224 + ASRo292
were used. In all cases, pDR111-Pspank‑hy-spaS was used as
template DNA for amplification of the subtilin leader peptide
sequences. To create PCR fusion products of a particular
leader and core peptide sequence, the PCR products of the
particular leader and core peptide were mixed together in a
PCR reaction and a primer pair was added allowing for
amplification of the fusion product. To generate spaASPRL-
spaS primers, ASRo224 and ASRo241 were used. To obtain
spaL-nisA, spaASPRL-nisA, spaL-f laA, and spaASPRL-f laA
primers ASRo224 and ASRo291 were used. The PCR fusion
products were digested with EcoRI and SphI and ligated into
similarly digested pDR111 yielding the pDR111 vectors
containing Pspank‑hy and the various structural genes. To insert
Pspank-spaBTC into the various pDR111 vectors, pDR111-
Pspank‑hy-spaS and pDR111-Pspank‑hy-spaASPRL-spaS were line-
arized by PCR via primer pair 333-pDR-Eco_fw and 334-pDR-
Eco_rv, whereas the four pDR111 vectors containing either
nisA or f laA were linearized using primer pair 375-pDR-Phs-
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bb-fw-Eco and 376-pDR-Phs-bb-rv-Eco. The Pspank-spaBTC
insert was amplified from pDG1664-Pspank-spaBTC using
primer pair 291_fw_Pspank and 335-pDG-Ps-BTC-Eco-rv.
BsaI-digestion of the pDR111 precursor backbones and Pspank-
spaBTC yielded the pDR111 vectors containing Pspank-spaBTC
downstream of one of the six different precursor peptides. The






To construct pDR111-PspaS-spaBTC-PspaS-spaS, pDR111 was
linearized and Pspank‑hy was removed by PCR amplification with
primers 145-pDR111-QF-F and 146-pDR111-QF-R. The
spaBTC and spaS coding regions including their native
promoters were PCR amplified from the genomic DNA of B.
subtilis ATCC 6633 by using primer pairs 147-spaBTCS-F and
148-spaBTCS-R. Quick-Fusion ligation resulted in pDR111-
PspaS-spaBTC-PspaS-spaS.
To construct the four different pJOE8999 vectors for
deletion of spaS, replacement of spaS by spaASPRL-nisA or
spaASPRL-f laA (in B. subtilis ATCC 6633), or for reintro-
duction of xylR in sacA (in PG10), a specific single guide RNA
(sgRNA)-encoding sequence (Supplementary Table 3) was
designed by using the CRISPR Guide Design Software of
Benchling and cloned into pJOE8999 via BsaI digestion. To
allow homologous recombination, up- and downstream
flanking regions to construct pJOE_ΔspaS were obtained
from the genomic DNA of B. subtilis ATCC 6633 using primer
pairs ΔspaS_up-fw + ΔspaS_up-rv and ΔspaS_down-fw +
ΔspaS_down-rv. BsaI-digestion of PCR products followed by
ligation into the similarly digested pJOE vector containing the
spaS spacer sequence yielded pJOE_ΔspaS. To construct
pJOE_nisA and pJOE_flaA, flanking regions were obtained
from the genomic DNA of B. subtilis ATCC 6633 via primer
pairs 209-spaS_up-F-SfiI + 210-spaS_up-R-SfiI and 211-
spaS_down-F-SfiI + 212-spaS_down-R-SfiI, respectively. The
spaASPRL-nisA and spaASPRL-f laA inserts were amplified from
pDR111-Pspank‑hy-spaASPRL-nisA and pDR111-Pspank‑hy-
spaASPRL-flaA by using 206-spaL-F-SfiI as forward primer
and 207-nisA-R-SfiI or 208-flaA-R-SfiI as reverse primer,
respectively. To obtain the final vectors of pJOE_nisA and
pJOE_flaA, flanking regions and inserts were digested with Sf iI
followed by ligation into the similarly digested pJOE vector
with the spaS spacer sequence. To construct pJOE_xylR,
primer pairs 275-sacA1-Fw-Eco + 276-sacA1-Rv-Eco and 279-
sacA2-Fw-Eco + 280-sacA2-Rv-Eco were used for amplification
of the flanking regions, while xylR with its natural promoter
was amplified from the genomic DNA of B. subtilis 168 using
primers 277-XylR-Fw-Eco + 278-XylR-Rv-Eco. After lineariza-
tion of pJOE with the spacer sequence for recognition of sacA
via PCR with primers 281-pJOE_sacA-Eco and 282-
pJOE_sacA-Eco, BsaI-digestion of the PCR products followed
by ligation yielded the final pJOE_xylR vector.
Protease Gene Expression Constructs. The genetic
sequences of wprA, aprE, vpr, epr, and bpr were PCR amplified
from the genomic DNA of B. subtilis ATCC 6633 by using the
following primer pairs: 77-wprA-F-SalI + 79-wprA-R-PaeI, 81-
aprE-F-SalI + 83-aprE-R-PaeI, 86-vpr-F-NheI + 87-vpr-R-PaeI,
105-epr-F-SalI + 106-epr-R-NheI, and 108-bpr-F-SalI-RBS +
109-bpr-R-NheI, respectively. PCR products were digested
according to the restriction sites introduced by PCR
amplification and ligated into similarly digested pDR111,
yielding the various pDR111 protease overexpression vectors.
Production of Lantibiotic Peptides and Proteases. For
the heterologous expression of the lantibiotic or protease genes
by various B. subtilis strains, overnight cultures were diluted to
a final OD600 of 0.075 into 50 mL of fresh LB and grown at 37
°C and 220 rpm. Cultures were induced at midexponential
phase with either 0.2% (v/v) of culture supernatant from B.
subtilis ATCC 6633 (containing subtilin), 1% xylose, and/or 1
mM IPTG. After 3 h, the growth medium was separated from
the cells by centrifugation, and in case of the lantibiotic gene
expression strains the culture supernatant was concentrated
(125-fold) by trichloroacetic acid (TCA) precipitation. For
this purpose, peptide pellets were obtained by centrifugation
(1 h, 9000 rpm, 4 °C), washed with ice-cold acetone (1 h,
8500 rpm, 4 °C), air-dried, and solubilized in 0.05% acetic
acid. The cell lysate fraction of PG10 WprA was obtained by
bead beating of cells resuspended in 30 mM Tris-HCl pH 7.5
containing 0.5% n-dodecyl β-maltoside (DDM).
Peptide Detection. For tricine SDS-PAGE, a 16%
separating gel was used. After separation of proteins, proteins
were visualized by using Coomassie Brilliant Blue G-250 (Bio-
Rad, Hercules, United States).
For MALDI-TOF MS, a 1 μL sample of TCA-precipitated
culture supernatant was spotted and dried on the target.
Subsequently, 1 μL of matrix solution (4 mg/mL α-cyano-4-
hydroxycinnamic acid from Sigma-Aldrich dissolved in 50%
acetonitrile and 0.1% trifluoroacetic acid) was spotted on top
of the sample. Mass spectra were collected by using a Voyager
DE PRO matrix-assisted laser desorption ionization-time-of-
flight (MALDI-TOF) mass spectrometer (Applied Biosys-
tems). For analysis of the mass spectra “Data Explorer”
software version 4.0.0.0 (Applied Biosystems) was used.
Antimicrobial Activity Assay. To assess antimicrobial
activity, indicator plates were prepared composed of LB agar
and 0.2% (v/v) of an overnight culture of M. luteus. An 8 μL
aliquot of the TCA-precipitated culture supernatant was
pipetted on the plate, and if desired, combined with 2 μL of
purified NisP or trypsin (0.1 mg/mL), 4 μL of B. subtilis 168
supernatant, or 4 μL of supernatant or cell lysate derived from
the PG10 protease overexpression strains. For Table 2,
diameters of growth inhibition zones were measured to assess
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